Navigation Links
IACP: FDA Authority Is Clear, Direct, And Certain

WASHINGTON, Nov. 20, 2012 /PRNewswire-USNewswire/ -- The International Academy of Compounding Pharmacists (IACP) today asked U.S. Food and Drug Administration (FDA) Commissioner Margaret Hamburg to explain why the agency did not take specific actions to address complaints it had received about the New England Compounding Center, the company that according to federal officials is responsible for 33 deaths and the illness of over 400 more in the current outbreak of meningitis.


In a letter to Hamburg, IACP Executive Vice President and CEO David Miller, R.Ph. identified the specific federal laws and regulations that authorize that federal agency to shut down illegal drug manufacturers like the New England Compounding Center (NECC).

While acknowledging that changes may be needed in some areas to address federal and state oversight of the compounding profession, IACP said it is necessary first to determine why the existing authority of the FDA was not exercised before the health of scores of Americans was placed at risk.

"The federal Food, Drug and Cosmetic Act's existing inspection provision, Section 704, allows FDA clear, direct, and certain oversight when a pharmacy is not operating in conformity with governing state laws, or is operating akin to a drug manufacturer," Miller said in his letter to the FDA.  Last week Miller testified before the United States Senate Committee on Health, Education, Labor, and Pensions at its Thursday hearing on the meningitis outbreak.

Congressional investigators have requested documents from the FDA that would shed light on why the New England Compounding Center was allowed to continue operating even after complaints about practices there were received by the Massachusetts State Board of Pharmacy and the FDA. The FDA has not yet produced those documents, and Miller said he agreed with U.S. House and Senate members that the internal history regarding NECC is important before changes in the law are contemplated.

Miller further asked the FDA to provide a description of its standard operating procedure for cases – like that involving NECC – where a company is identified as being a manufacturer of drugs, and a possible violator, even though it is not registered as a manufacturer.

"The IACP and its members strongly urge the FDA to explain the delays and inaction in the tragic case of the NECC, to identify which staff members were involved, to provide a timeline surrounding complaints about NECC, and to specify why decisions were made to let the company continue operating," Mr. Miller said in his letter.

Although NECC portrayed itself as a compounding pharmacy, it in fact operated as a drug manufacturer. Though it was not formally registered as a manufacturer with the FDA, the company was clearly subject to oversight by the FDA, Miller said in his letter today to Hamburg, elaborating on his testimony before Congress last week.

Miller's testimony was at odds with that of with that of Hamburg, who contended that the FDA's authority over companies like NECC is unclear. "IACP insists that we determine what went on with NECC, and why the FDA did not act under existing regulations," Miller said.

A copy of the letter to the FDA from the IACP was also sent to the President of the Massachusetts State Board of Pharmacy, which has jurisdiction over compounding pharmacies in the state and had been notified of complaints about NECC.


The International Academy of Compounding Pharmacists (IACP), based in Missouri City, TX, is an international, professional association established in 1991 to protect, promote and advance the art and science of pharmacy compounding. For more information, please go to

Contact: David Ball, Ball Consulting Group, LLC
On behalf of IACP
O: 617-243-9950

SOURCE International Academy of Compounding Pharmacists (IACP)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. UBM Canon, the Global Authority on the MedTech Industry, Announces Key Hire in Germany to Complement Its Expanding Media and Marketing Solutions Team
2. UBM Canon, the Global MedTech Authority, and the Medical Design Excellence Awards Honored Dr. Thomas Fogarty with the 2012 Lifetime Achievement Award
3. UBM Canon, the Global MedTech Authority, Partners with the World Medical Device Organization, WMDO, to Provide Medical Device Companies with Industry-Related Online Training Solutions
4. UBM Canon, the Global MedTech Authority, Announces Strategic Alliance with ITG Market Research, a Preeminent Industry Research Organization
5. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
6. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma ... as the company,s second affiliate in Latin America . ... ... Astellas Farma Colombia ... ...
(Date:6/23/2016)... , June 23, 2016 ... "Surgical Procedure Volumes: Global Analysis (United States, China, ... Canada)" report to their offering. ... essential tool for healthcare business planners, provides surgical procedure ... at surgery trends with an in-depth analysis of growth ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):